AbbVie's current clinical roster contains many combination therapies and follow-on indications in oncology and immunology, but early-stage assets from licensing and acquisition deals made this decade are making their way to the clinical pipeline.
With a decent war chest and analysts calling for acquisitions, AbbVie must decide which of its areas of focus to concentrate on. In recent years, they have struck up collaborations in oncology and immunology, but in light of Gilead, Celgene and Novartis' massive leads in T-cell engineered therapies in oncology, AbbVie may be wise to invest in other areas.
AbbVie's last deal of 2017 and first deal of 2018 - both for potential therapies for Alzheimer's Disease and other neurodegenerative disorders - adds to the small number of neurodegenerative therapies currently in clinical trials.
Since Pfizer announced their exit from neuroscience in January 2018, AbbVie is in a position to consider filling - at least in part - Pfizer's empty neuroscience boots.
Be first to receive new white papers, industry intelligence and product announcements.